GEN Exclusives

More »

GEN News Highlights

More »
Dec 12, 2006

Invitrogen Secures Blue Heron Bio’s Gene Synthesis Service

  • Invitrogen will invest in Blue Heron in exchange for worldwide rights to distribute the company’s custom gene synthesis services, under a strategic development and distribution deal.

    Blue Heron Biotechnology's GeneMaker® platform can synthesize any gene sequence, with perfect accuracy regardless of length or complexity, which makes it ideal for the synthetic biology market, the companies report.

    "Invitrogen recognizes the tremendous new possibilities that gene synthesis offers life science researchers," says Nathan Wood, vp of cloning and protein expression, Invitrogen. "We have developed a broad array of products that complement Blue Heron's GeneMaker platform and this agreement continues to enhance our portfolio offerings to our customers."

    As part of the agreement, the companies will co-develop new products and services for the research and biopharmaceutical markets.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »